Mark G. Frattini

11.3k total citations · 1 hit paper
75 papers, 3.4k citations indexed

About

Mark G. Frattini is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Mark G. Frattini has authored 75 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 27 papers in Hematology and 23 papers in Oncology. Recurrent topics in Mark G. Frattini's work include Acute Myeloid Leukemia Research (25 papers), Chronic Myeloid Leukemia Treatments (12 papers) and DNA Repair Mechanisms (11 papers). Mark G. Frattini is often cited by papers focused on Acute Myeloid Leukemia Research (25 papers), Chronic Myeloid Leukemia Treatments (12 papers) and DNA Repair Mechanisms (11 papers). Mark G. Frattini collaborates with scholars based in United States, France and Australia. Mark G. Frattini's co-authors include Laimonis A. Laimins, Craig Meyers, John B. Hudson, Anthony Letai, Courtney D. DiNardo, Hagop M. Kantarjian, Steven L. Dresler, Daniel A. Pollyea, Andrew H. Wei and Keith W. Pratz and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Mark G. Frattini

75 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Keith W. Pratz et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Mark G. Frattini

Since Specialization

Citations

This map shows the geographic impact of Mark G. Frattini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark G. Frattini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark G. Frattini more than expected).

Fields of papers citing papers by Mark G. Frattini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark G. Frattini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark G. Frattini. The network helps show where Mark G. Frattini may publish in the future.

Co-authorship network of co-authors of Mark G. Frattini

This figure shows the co-authorship network connecting the top 25 collaborators of Mark G. Frattini. A scholar is included among the top collaborators of Mark G. Frattini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark G. Frattini. Mark G. Frattini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome 2022 ·Journal of Cancer Research and Clinical Oncology ·Courtney D. DiNardo, Andreas Hochhaus, Mark G. Frattini, Karen Yee, Thomas Zander, Alwin Krämer, Xueying Chen, Yan Ji, Nehal S. Parikh, Joanne Jung Eun Choi, Andrew H. Wei	22
2	Human DDK rescues stalled forks and counteracts checkpoint inhibition at unfired origins to complete DNA replication 2021 ·Molecular Cell ·Mathew V. Jones, Camille Gelot, (unknown), Amnon Koren, (unknown), Kelly A. George, (unknown), Jesper V. Olsen, Steven A. McCarroll, Mark G. Frattini, Tatsuro Takahashi, Prasad V. Jallepalli	21
3	Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial 2021 ·The Lancet Oncology ·Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton, Amer M. Zeidan, Amir T. Fathi, Hagop M. Kantarjian, John M. Bennett, Mark G. Frattini, Patricia Martin‐Regueira, Frederik Lersch, Jing Gong, Maroof Hasan, Paresh Vyas, Hartmut Döhner	127
4	Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia 2020 ·Clinical Cancer Research ·Joshua F. Zeidner, Daniel J. Lee, Mark G. Frattini, (unknown), (unknown), Kathryn S. Kolibaba, Stephen P. Anthony, David J. Bearss, B. Douglas Smith	18
5	Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial 2020 ·The Lancet Haematology ·Eytan M. Stein, Amir T. Fathi, Courtney D. DiNardo, Daniel A. Pollyea, Gail J. Roboz, Robert H. Collins, Mikkael A. Sekeres, Richard M. Stone, Eyal C. Attar, Mark G. Frattini, Alessandra Tosolini, Qiang Xu, Wendy L. See, Kyle J. MacBeth, Stéphane de Botton, Martin S. Tallman, Hagop M. Kantarjian	79
6	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure 2018 ·Clinical Cancer Research ·Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David A. Rizzieri, Mark G. Frattini, Yair Levy, Mark A. Schroeder, Anna Ferguson, (unknown), Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith	74
7	Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA 2018 ·Nature Communications ·Demis Menolfi, Wenxia Jiang, Brian J. Lee, Tatiana N. Moiseeva, Zhengping Shao, Verna M. Estes, Mark G. Frattini, Christopher J. Bakkenist, Shan Zha	35
8	192 Gene expression profiling of mechlorethamine and romidepsin combination shows downregulation of the JAK/STAT pathway in cutaneous T-cell lymphoma 2018 ·Journal of Investigative Dermatology ·(unknown), Marta Sánchez-Martín, S. Aidan Quinn, Mark G. Frattini, Adolfo A. Ferrando, Teresa Palomero, Larisa J. Geskin	1
9	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study breakdown → 2018 ·The Lancet Oncology ·Courtney D. DiNardo, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Michael J. Thirman, Martha Arellano, Mark G. Frattini, Hagop M. Kantarjian, Relja Popovic, Brenda Chyla, Tu Xu, Martin Dunbar, Suresh Agarwal, Rod Humerickhouse, Mack Mabry, Jalaja Potluri, Marina Konopleva, Daniel A. Pollyea	498
10	Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literature 2013 ·Leukemia & lymphoma ·Elizabeth H. Cull, Justin M. Watts, Martin S. Tallman, Peter Kopp, Mark G. Frattini, Franck Rapaport, Raajit K. Rampal, Ross L. Levine, Jessica K. Altman	8
11	An Arrayed Genome-Scale Lentiviral-Enabled Short Hairpin RNA Screen Identifies Lethal and Rescuer Gene Candidates 2012 ·Assay and Drug Development Technologies ·Bhavneet Bhinder, Christophe Antczak, Christina N. Ramirez, David Shum, (unknown), Constantin Radu, Mark G. Frattini, Hakim Djaballah	10
12	Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML 2012 ·Cell ·Thanh‐Trang Vo, Jeremy Ryan, Ruben D. Carrasco, Donna Neuberg, Derrick J. Rossi, Richard M. Stone, Daniel J. DeAngelo, Mark G. Frattini, Anthony Letai	266
13	Comparison of Luminescence ADP Production Assay and Radiometric Scintillation Proximity Assay for Cdc7 Kinase 2011 ·Combinatorial Chemistry & High Throughput Screening ·Toshimitsu Takagi, David Shum, Monika Parisi, (unknown), Constantin Radu, (unknown), (unknown), Mark G. Frattini, Hakim Djaballah	11
14	Identification of benzofuran-4,5-diones as novel and selective non-hydroxamic acid, non-peptidomimetic based inhibitors of human peptide deformylase 2011 ·Bioorganic & Medicinal Chemistry Letters ·Christophe Antczak, David Shum, Bhramdeo Bassit, Mark G. Frattini, Yue‐Ming Li, Elisa de Stanchina, David A. Scheinberg, Hakim Djaballah	19
15	Preclinical Assessment of a Novel CDC7 Inhibitor: Genomewide RNAi Screening Identifies Unique Synergetic and Resistance Genes, 2011 ·Blood ·(unknown), Bhavneet Bhinder, David Shum, Christina N. Ramirez, Constantin Radu, (unknown), Mark G. Frattini	1
16	An exo-cell assay for examining real-time γ-secretase activity and inhibition 2009 ·Molecular Neurodegeneration ·Christopher C. Shelton, Yuan Tian, Mark G. Frattini, Yue‐Ming Li	18
17	Multiple Mechanisms Contribute to Schizosaccharomyces pombe Origin Recognition Complex-DNA Interactions 2008 ·Journal of Biological Chemistry ·Christopher R. Houchens, Wenyan Lü, Ray-Yuan Chuang, Mark G. Frattini, (unknown), (unknown), Thomas J. Kelly	27
18	Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein 1997 ·The EMBO Journal ·Mark G. Frattini	60
19	The Role of the E1 and E2 Proteins in the Replication of Human Papillomavirus Type 31b 1994 ·Virology ·Mark G. Frattini, Laimonis A. Laimins	70
20	Analysis of butylphenyl-guanine, butylphenyl-deoxyguanosine, and butylphenyl-deoxyguanosine triphosphate inhibition of DNA replication and ultraviolet-induced DNA repair synthesis using permeable human fibroblasts 1988 ·Biochemical Pharmacology ·Steven L. Dresler, Mark G. Frattini	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact